News

Valneva Announces New $59 Million IXIARO® Supply Contract with US Government

Valneva announced the signing of a new $59 million contract with the U.S. government Department of Defense for the supply of its Japanese encephalitis…

Read more

Valneva Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019

Valneva confirmed its revenue and product sales guidance for 2018 and provided initial product sales guidance for 2019.

Read more

Valneva Reports Positive Phase 1 Interim Results for Its Chikungunya Vaccine Candidate

Phase 1 interim results showed an excellent immunogenicity profile after a single-shot vaccination and an acceptable safety profile, supporting…

Read more

The biomechanics of vascular ageing

Cardiovascular Diseases (CVD) lead to atherosclerosis and heart failure and are prevalent age-related illnesses in humans. In a new study, published…

Read more

Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test

Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency, and initiates set-up of R&D and service…

Read more

Valneva Announces its Intention to Delist from the Vienna Stock Exchange

Valneva announced that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science…

Read more

University of Vienna and Medical University of Vienna extend successful collaboration with Max F. Perutz Laboratories

The University of Vienna and Medical University of Vienna are extending their successful collaboration with Max F. Perutz Laboratories. Rectors Heinz…

Read more

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

The agreement grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave® investigational arenavirus-based immunization technologies for the…

Read more

Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate

Valneva announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its chikungunya vaccine candidate, VLA1553. …

Read more

New Managing Director at VBCF

In January 2019, the new Managing Director of the Vienna BioCenter Core Facilities GmbH, Daniele Soroldoni, has started his work. Welcome!

Read more

Austrian-Czech project provides open access to research infrastructure

Call for proposals remains open as long as capacity exists

Read more

VBC Summer School 2019 application deadline: 31 January 2019

The Vienna Biocenter Summer School provides a unique opportunity for approx. 28 undergraduate students to work side-by-side with leading researchers…

Read more